There are currently 66 clinical trials in Mckinney, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Texas Oncology- McKinney, North Dallas Research Associates, Novartis Investigative Site and Metroplex Pulmonary and Sleep Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351
Recruiting
The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Texas Institute of Cardiology, McKinney, Texas
Conditions: Severe Hypertriglyceridemia
Register for Updates
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652
Recruiting
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/03/2025
Locations: Research Site, McKinney, Texas
Conditions: Heart Failure and Impaired Kidney Function
Register for Updates
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
02/27/2025
Locations: Wellness Clinical Research, McKinney, Texas
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Register for Updates
A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Ear Nose and Throat Associates of Texas PA, McKinney, Texas
Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Register for Updates
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
NCT05813288
Recruiting
The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
02/24/2025
Locations: Research Site 30001-295, McKinney, Texas
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Register for Updates
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: USO - Texas Oncology, McKinney, Texas
Conditions: Breast Neoplasms
Register for Updates
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
NCT06496620
Recruiting
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
02/20/2025
Locations: Research Site 012, McKinney, Texas
Conditions: COPD
Register for Updates
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
NCT06102005
Recruiting
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/16/2025
Locations: Metroplex Pulmonary and Sleep Center- Site Number : 8400022, McKinney, Texas
Conditions: Asthma
Register for Updates
A Study of RSLV-132 in Females with Sjögren's Syndrome
NCT06440525
Recruiting
The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132. The main questions it aims to answer are: * Does RSLV-132 improve the cardinal symptoms of Sjogren's including fatigue, dryness and pain? * Does RSLV-132 improve the tiredness/fatigue caused by Sjogren's? * What are the blood levels of RSLV-132 over time? * What is the immune (antibody) response in the body to RSLV-132? * What is the safety profile of R... Read More
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
02/14/2025
Locations: Resolve Clinical Site, McKinney, Texas
Conditions: Primary Sjögren Syndrome
Register for Updates
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
NCT03953300
Recruiting
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/12/2025
Locations: Research Site, McKinney, Texas
Conditions: Asthma
Register for Updates
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants with Progressive Pulmonary Fibrosis
NCT06329401
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Metroplex Pulmonary and Sleep Center, PA, McKinney, Texas
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
A Study to Assess the Effects of Dexpramipexole in Participants with Eosinophilic COPD
NCT06533553
Recruiting
This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
01/30/2025
Locations: Research Site 10001-026, McKinney, Texas
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates